Cytomegalovirus infection in patients receiving bispecific antibodies for multiple myeloma and B-cell malignancies: a single-center cohort and meta-analysis
Open Access
- 26 August 2026
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1918863
Abstract
Background: Bispecific antibodies (BsAbs) are transformative therapies for multiple myeloma (MM) and B-cell malignancies. Cytomegalovirus (CMV) infection has been reported as a potential complication of unclear clinical magnitude. Methods: We conducted a retrospective study of MM patients treated with BsAbs at our institution (2020–2025), alongside a systematic review and meta-analysis of clinical trials and observational studies evaluating BsAbs for MM, B-cell lymphoma, and acute lymphoblastic leukemia. Study outcomes included clinically significant CMV infection (csCMVi), any CMV DNAemia, and CMV disease. Results: Our cohort included 98 BsAb therapy courses (74.5% anti-B-cell maturation antigen [BCMA]) with a median follow-up of 10.4 months. Cumulative incidence rates for csCMVi and CMV disease were 9.2% (9/98) and 3.1% (3/98), respectively. Factors associated with csCMVi at the univariable level were poorer functional status, prior allogeneic hematopoietic stem cell transplantation (allo-HSCT), grade 4 neutropenia, and grade ≥3 cytokine release syndrome (CRS). The meta-analysis (23 studies plus our single-center cohort comprising 2,956 BsAb courses) revealed a pooled cumulative incidence rates of 9% (95% confidence interval [CI]: 4–15%; I 2 96.11%) for csCMVi and 1% (95% CI: 0–2%; I 2 69.78%) for CMV disease. Incidence was notably higher in studies applying routine CMV DNAemia monitoring and with anti-BCMA agents. Conclusion: The occurrence of csCMVi or CMV disease during the course of BsAb therapy for MM or B-cell malignancies is uncommon, arguing against routine CMV DNAemia monitoring or antiviral prophylaxis. Prevention approaches, however, may be warranted in patients receiving anti-BCMA BsAbs with additional risk factors such as allo-HSCT or severe CRS. Systematic Review Registration: https://www.crd.york.ac.uk/prospero/ , identifier CRD420251162657.Keywords
Funding Information
- Instituto de Salud Carlos III (CM25/00250, CM25/00243, JR24/00034)
This publication has 40 references indexed in Scilit:
- Predicators and Outcomes of Cytomegalovirus Reactivation in Chimeric Antigen Receptor T-Cell Therapy: A Systematic ReviewClinical Lymphoma Myeloma and Leukemia, 2025
- Risk factors and clinical impact of cytomegalovirus DNAemia in patients with multiple myeloma treated with teclistamabBlood Neoplasia, 2025
- Effectiveness and infectious complications of BCMA T‐cell engagers in treating multiple myeloma: Real‐world evidence from SwedenCancer Medicine, 2024
- Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world studyBlood Cancer Journal, 2024
- Characteristics and incidence of infections in patients with multiple myeloma treated by bispecific antibodies: a national retrospective studyClinical Microbiology and Infection, 2024
- Mosunetuzumab Safety Profile in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma: Clinical Management Experience From a Pivotal Phase I/II TrialClinical Lymphoma Myeloma and Leukemia, 2023
- Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 studyCancer, 2023
- Infectious complications of bispecific antibody therapy in patients with multiple myelomaBlood Cancer Journal, 2023
- Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trialThe Lancet Haematology, 2022
- Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gapBlood Reviews, 2021